Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
SINTX Technologies furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1, which also discusses the company’s use of a non-GAAP financial measure.
The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference except as expressly stated. The Item 2.02 information is also included under Item 7.01 by reference.
SINTX Technologies filed its Q3 2025 10‑Q, reporting total revenue of $208k (down 74% year over year) and a net loss of $3.539M. Gross profit was $93k, with operating expenses of $3.448M driven by R&D $1.264M and G&A $2.102M. Cash and cash equivalents were $6.250M as of September 30, 2025.
The company continued shifting away from low‑margin OEM work toward proprietary silicon nitride medical devices. It received FDA 510(k) clearance in October 2025 for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected to begin in the first half of 2026. Q3 also included an inducement in which holders exercised warrants for ~$3.8M in gross proceeds, creating a $6.7M deemed dividend.
SINTX strengthened liquidity with a $6.41M at‑the‑market facility established in October 2025 and expects ~$950k savings from subleasing the armor facility. Management states no significant uncertainty regarding its ability to continue as a going concern through at least November 12, 2026. Shares outstanding were 3,851,956 as of November 7, 2025.
Sintx Technologies (SINT) insider activity: A company director and Chief Investment Officer reported open‑market purchases on 11/07/2025. The filer bought 5,000 shares at $3.20 and 5,000 shares at $3.18, increasing beneficial ownership to 74,000 shares, held directly.
SINTX Technologies (Nasdaq: SINT) filed a resale registration covering up to 1,741,539 shares of common stock to be offered by selling stockholders. The registered shares consist of 1,649,147 common warrant shares and 92,392 placement agent warrant shares issued in connection with a February 2025 private placement and an inducement letter dated September 8, 2025.
The company is not selling any shares in this prospectus and will not receive proceeds from selling stockholder resales. SINTX would receive up to approximately $8.3 million only if the warrants are exercised for cash; stated exercise prices include $4.79 for the common warrants and $4.3844 and $4.3125 for the placement agent warrants. Any cash received from exercises will be used for working capital and general corporate purposes.
Shares may be sold by the holders at market, fixed, related, or negotiated prices through various methods described in the plan of distribution. Shares outstanding were 3,683,989 as of October 20, 2025; this is a baseline figure, not the amount being registered. The last reported SINT price was $3.25 on October 22, 2025.
SINTX Technologies (SINT) filed a Form 4 reporting an insider purchase. The company’s President and CEO, who also serves as a director, purchased 5,800 shares of common stock on 10/20/2025 at a price of $3.4 per share.
Following this transaction, the reporting person beneficially owns 30,775 shares, held directly. The filing indicates it was submitted by one reporting person.
SINTX Technologies established an at-the-market stock offering program to sell common shares with an aggregate offering price of $6,413,876 through H.C. Wainwright as sales agent. The program uses the company’s effective Form S-3 shelf registration and a new prospectus supplement.
Wainwright will receive a 3.0% commission on the gross sales price of any shares sold, plus reimbursement of specified expenses. SINTX is not required to sell any stock, can suspend the program at any time, and will designate the maximum amount of stock to be sold in each placement.
Sintx Technologies, Inc. filed a prospectus supplement for a securities offering that discloses pro forma tangible book value and recent capital-raising activity. As of June 30, 2025 the company reported a net tangible book value per share of $1.60. Following the issuance of 723,873 shares in a warrant inducement offering that closed on September 8, 2025 for net proceeds of approximately $3.35 million, pro forma net tangible book value per share rose by $0.68 to $2.28. The current offering would further increase pro forma net tangible book value per share by $0.53, producing a pro forma as adjusted value of $2.81 per share and resulting in dilution to new investors of $1.28 per share.
The document contains table-of-contents material and references to incorporated filings and exhibits but does not provide full disclosure of the total shares outstanding immediately after the offering or detailed use-of-proceeds amounts in the excerpt provided.
SINTX Technologies, Inc. filed a Form S-8 registration statement to register shares of its common stock for issuance under the SINTX Technologies, Inc. 2025 Equity Incentive Plan. This filing allows the company to grant equity-based awards, such as stock options or other share-based incentives, to eligible participants.
The registration statement incorporates by reference SINTX’s recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and multiple Current Reports on Form 8-K, along with the description of its common stock. It also details Delaware-law based indemnification and exculpation protections for directors and officers and lists numerous warrant and indenture forms as exhibits. The document is signed by the Chief Executive Officer, Chief Financial Officer, and the board of directors.
SINTX Technologies, Inc. is registering 541,450 shares of common stock for resale by a single selling stockholder under an S-3 prospectus. The shares include 216,450 PIPE Shares issued in a private placement and 325,000 Warrant Shares issuable upon exercise of common warrants.
SINTX will not sell any shares in this offering and will not receive proceeds from the stockholder’s resales. It could receive up to approximately $2.05 million only if all 325,000 warrants are exercised for cash at an exercise price of $6.30 per share. As of September 26, 2025, 3,585,856 shares of common stock were outstanding, rising to 3,910,856 shares if all these warrants are exercised.
The company develops advanced silicon nitride ceramics for biomedical and antipathogenic uses, including spinal implants and osteotomy wedges, and notes that investing in its securities involves a high degree of risk, including potential dilution and stock price pressure from warrant-related share sales.
SiNtx Technologies, Inc. disclosed an agreement allowing holders to exercise existing warrants and receive new common stock purchase warrants. The holders may exercise existing warrants to acquire shares at $3.32 per share, and the company will issue New Warrants to purchase up to 1,649,147 common shares at $4.79 per share. Holders also agreed to pay $0.125 per New Warrant as consideration. The company expects to receive aggregate gross proceeds of approximately $3.8 million from exercise of the existing warrants, before placement agent fees and other offering expenses. The filing includes forms for the inducement letter, New Warrant, placement agent warrants and related exhibits, and is signed by CEO Eric K. Olson.